Brii Biosciences Limited
BRIBF
$0.2406
$0.00944.07%
OTC PK
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -100.00% |
| Total Other Revenue | 76.56% | 77.96% | -45.70% | -46.52% | -63.66% |
| Total Revenue | 76.56% | 77.96% | -46.53% | -47.34% | -83.53% |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | 76.56% | 77.96% | -46.53% | -47.34% | -83.53% |
| SG&A Expenses | -1.08% | -0.29% | 3.62% | 2.05% | 8.96% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -26.31% | -25.72% | -24.91% | -26.05% | 8.54% |
| Operating Income | 32.14% | 31.60% | 21.65% | 22.84% | -58.95% |
| Income Before Tax | -1,946.42% | -1,961.17% | -39.25% | -37.14% | 109.87% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -1,946.42% | -1,961.17% | -39.25% | -37.14% | 109.87% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -42.18% | -41.72% | -62.15% | -62.73% | 120.63% |
| Net Income | -1,614.34% | -1,626.34% | -42.93% | -40.77% | 110.86% |
| EBIT | 32.14% | 31.60% | 21.65% | 22.84% | -58.95% |
| EBITDA | 31.96% | 31.56% | 21.26% | 22.45% | -61.29% |
| EPS Basic | -1,650.00% | -1,657.14% | -42.47% | -40.31% | 110.53% |
| Normalized Basic EPS | -90.91% | -90.91% | 29.71% | 30.99% | 57.28% |
| EPS Diluted | -1,650.00% | -1,657.14% | -42.47% | -40.31% | 110.53% |
| Normalized Diluted EPS | -90.91% | -90.91% | 29.71% | 30.99% | 57.28% |
| Average Basic Shares Outstanding | 0.28% | 0.28% | 0.31% | 0.31% | 0.49% |
| Average Diluted Shares Outstanding | 0.28% | 0.28% | 0.31% | 0.31% | 0.49% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |